Roche’s Gantenerumab May Rise From The Alzheimer’s Ashes
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma has renewed interest in the anti-amyloid beta antibody – which failed a large Phase III trial - after Biogen released positive early data on a similar rival compound.